Laboratory for Structure, Faculty of Pharmaceutical Science, Tokushima Bunri University, Tokushima, Japan.
Oncol Rep. 2011 Oct;26(4):783-7. doi: 10.3892/or.2011.1385. Epub 2011 Jul 11.
Oral mucosal melanoma (OMM) is a fatal sarcoma of unknown etiology. Histological morphology and genetic events are distinct from those of its cutaneous counterpart. Mutation and up-regulation of c-kit has been identified in OMM which may activate downstream molecules such as RAS and RAF. These molecules are involved in the mitogen-activated protein kinase (MAPK) pathway leading to tremendous cell proliferation and survival. NRAS and BRAF mutation and protein expression have been studied in other melanoma subtypes. The purpose of this study was to determine RAS protein expression and NRAS and BRAF mutation in 18 primary OMM cases using immunohistochemistry and mutation analysis. Results showed that RAS is intensely expressed in both in situ and invasive OMMs. However, NRAS mutation was only observed in 2/15 polymerase chain reaction (PCR) amplified cases both of which were silent mutations. On the other hand, BRAF missense mutations were observed only in 1/15 cases with PCR amplification. NRAS and BRAF mutations were independent from previously reported c-kit mutations. The classical V600E BRAF mutation was not found; instead a novel V600L was observed suggesting that the oncogenic event in OMM is different from that in skin melanoma. The low frequency of NRAS and BRAF mutations indicate that these genes are not common, but probable events in OMM pathogenesis, most likely independent of c-kit mutation.
口腔黏膜黑色素瘤(OMM)是一种病因不明的致命肉瘤。其组织形态学和遗传事件与皮肤黑色素瘤不同。在 OMM 中已鉴定出 c-kit 的突变和上调,这可能会激活下游分子,如 RAS 和 RAF。这些分子参与丝裂原活化蛋白激酶(MAPK)途径,导致大量细胞增殖和存活。NRAS 和 BRAF 突变和蛋白表达已在其他黑色素瘤亚型中进行了研究。本研究的目的是使用免疫组织化学和突变分析来确定 18 例原发性 OMM 病例中的 RAS 蛋白表达以及 NRAS 和 BRAF 突变。结果表明,RAS 在原位和侵袭性 OMM 中均强烈表达。然而,仅在 2/15 个经聚合酶链反应(PCR)扩增的病例中观察到 NRAS 突变,且均为沉默突变。另一方面,仅在 1/15 个经 PCR 扩增的病例中观察到 BRAF 错义突变。NRAS 和 BRAF 突变与先前报道的 c-kit 突变无关。未发现经典的 V600E BRAF 突变,而是观察到新型 V600L,这表明 OMM 中的致癌事件与皮肤黑色素瘤不同。NRAS 和 BRAF 突变的低频率表明这些基因在 OMM 发病机制中并不常见,但可能是事件,很可能独立于 c-kit 突变。